Related information

Group members

  • Olle Melander, group leader
  • Sofia Enhörning
  • Patrik Färbom
  • Gustav Smith
  • Jonas Dahlberg
  • Lena Nilsson

Hypertension and Cardiovascular Disease

Department of Clinical Sciences Malmö

Head: Olle Melander

There is a growing need of better and interventional tools for primary prevention of cardiovascular disease (CVD).  Our aim is to improve CVD risk prediction and to identify mechanisms causally related to CVD development in order to provide novel targets for drug discovery and targeted life style interventions for use in primary prevention.

  1. We perform targeted and whole exome sequencing in early CVD cases and controls and evaluate identified variants by relating them to incident CVD in 60 000 individuals.
  2. We test whether the plasma metabolome- a phenotype representing the product of dietary intake and inherent metabolism- differs between incident CVD cases and controls and between individuals with high and low genetic CVD risk. We further test whether a life style intervention differentially alters the plasma metabolome between individuals with high and low genetic CVD risk and elucidate mechanisms underlying CVD genetic associations by testing whether heart function, experimental myocardial infarction size and the plasma metabolome are affected by adenoviral transfer of genes, associated with CVD in humans, into rat myocardium.
  3. We test whether glucose metabolism and CVD risk factors can be ameliorated by suppressing vasopressin (VP) by increased water intake in humans. Finally, we test which of the 3 VP receptors is responsible for adverse glucometabolic VP effects by specific VP receptor pharmacological studies in rats.

By creating and integrating new knowledge on the role of genomics, metabolomics and the vasopressin system in cardiometabolic disease we hope to: (1) Significantly improve CVD risk prediction (2) provide novel and targeted life style interventions for CVD prevention and (3) identify novel mechanisms causally related to CVD in humans and thereby provide new drug targets for CVD prevention.

Five recent original publications

Melander Olle, Newton-Cheh Christopher, Almgren Peter, Hedblad Bo, Berglund Göran, Engström Gunnar, Persson Head Nurse/PhD Margaretha, Persson Head Nurse/Researcher Margaretha, Smith Gustav, Magnusson Martin, Christensson Anders, Struck Joachim, Morgenthaler Nils G, Bergmann Andreas, Pencina Michael J, Wang Thomas J

Newton-Cheh Christopher, Larson Martin G., Vasan Ramachandran S., Levy Daniel, Bloch Kenneth D., Surti Aarti, Guiducci Candace, Kathiresan Sekar, Benjamin Emelia J., Struck Joachim, Morgenthaler Nils G., Bergmann Andreas, Blankenberg Stefan, Kee Frank, Nilsson Peter, Yin Xiaoyan, Peltonen Leena, Vartiainen Erkki, Salomaa Veikko, Hirschhorn Joel N., Melander Olle, Wang Thomas J.

Enhörning Sofia, Wang Thomas J, Nilsson Peter, Almgren Peter, Hedblad Bo, Berglund Göran, Struck Joachim, Morgenthaler Nils G, Bergmann Andreas, Lindholm Eero, Groop Leif, Lyssenko Valeria, Orho-Melander Marju, Newton-Cheh Christopher, Melander Olle

Kathiresan Sekar, Melander Olle, Anevski PhD Dragi, Guiducci Candace, Burtt Noël, Roos Charlotta, Hirschhorn Joel N, Berglund Göran, Hedblad Bo, Groop Leif, Altshuler David M, Newton-Cheh Christopher, Orho-Melander Marju

Magnusson Martin, Jujic Amra, Hedblad Bo, Engström Gunnar, Persson Head Nurse/PhD Margaretha, Persson Head Nurse/Researcher Margaretha, Struck Joachim, Morgenthaler Nils G, Nilsson Peter, Newton-Cheh Christopher, Wang Thomas J, Melander Olle

Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.JAMA : the journal of the American Medical Association. 2009; 302: 49 - 57 Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressureNature Genetics. 2009; 41: 348 - 353 Plasma copeptin and the risk of diabetes mellitus.Circulation. 2010; 121: 2102 - 2108 Polymorphism associated with cholesterol and risk of cardiovascular eventsNew England Journal Medicine. 2008; 358: 1240 - 1249 Low Plasma Level of Atrial Natriuretic Peptide Predicts Development of Diabetes: The Prospective Malmo Diet and Cancer Study.The Journal of clinical endocrinology and metabolism. 2011; Nov 23: -

Last updated: May 23, 2012
Website contact: LUDC webteam

LUDC, CRC, SUS Malmö, Entrance 72, House 91:12. SE-205 02 Malmö. Telephone: +46 40 39 10 00